This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients (PTOLEMY-2)

This study has suspended participant recruitment.
(Company ended operations January 2011)
Duke University
Medifacts International Corporation
Information provided by:
Viacor Identifier:
First received: November 5, 2008
Last updated: February 10, 2011
Last verified: February 2011
Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device.

Condition Intervention Phase
Heart Failure Mitral Regurgitation Device: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure

Resource links provided by NLM:

Further study details as provided by Viacor:

Primary Outcome Measures:
  • Freedom from MACE at 30 days post-procedure and quantitative MR reduction at 6 months [ Time Frame: 30 days to 6 months ]

Secondary Outcome Measures:
  • % of patients experiencing procedure or device-related adverse events [ Time Frame: 30 days to 6 months ]
  • Technical procedural success: % of patients maintaining a reduction of mitral annulus A/P dimension, sustained MR reduction, and decrease in left ventricular dimensions to specified degrees [ Time Frame: 6 months ]
  • Clinical status: % of treated patients exhibiting improvements in defined QoL parameters [ Time Frame: 6 months ]

Estimated Enrollment: 30
Study Start Date: October 2008
Estimated Study Completion Date: November 2015
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
Device: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Functional MR 2+ - 4+
  • Symptomatic heart failure, NYHA Class II to IV
  • LVEF > 25% or < 50% OR dilated mitral annulus > 30mm

Exclusion Criteria:

  • MR of organic origin
  • Severe mitral leaflet tethering
  • History of MI or PCI within 60 days of study procedure
  • Inability to walk a minimum of 100 meters in 6 minutes
  • Significant left main stenosis or proximal circumflex stent
  • Indication of non-patent CSO or discontinuous CS-GCV-AIV
  • Bi-ventricular with leads in CS or other devices impeding device placement
  • Severe aortic valvular disease
  • Chronic corticosteroid use other than < 20mg prednisone for arthritis
  • Significant co-morbidities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00787293

Onze Lieve Vrouw Ziekenhuis Cardiovasculair Ondrezoek Aalst
Aalst, Belgium, B-9300
Centre Hospitalier Universitaire de Liège
Liège, Belgium, B-4000
Czech Republic
Institut Klinicke a Experimentalni Mediciny
Prague, Czech Republic, 1958/9
Rheinisch-Westfalische Technische Hochschule Universitaetsklinikum Aachen
Aachen, Germany, D-52074
Herz-und Diabeteszentrum Nordrhein-Westfalen / Ruhr University of Bochum
Bad Oeynhausen, Germany, D-32545
Universitaet Duisburg-Essen Westdeutsches Herzzentrum Universitaetsklinikum Essen
Essen, Germany, D-45122
CardioVascular Center Frankfurt Sankt Katharinen
Frankfurt, Germany, D-60389
Albert-Ludwigs-Universitat Freiburg Mediziniche Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany, D-79095
Städtische Klinikum Karlsruhe GmbH
Karlsruhe, Germany, D-76133
Klinikum Schwabing Städtisches Klinikum München GmbH
München, Germany, D-80804
Thoraxcentrum Erasmus Medisch Centrum
Rotterdam, Netherlands, N-3015
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, N-3584
Hôpital Universitaire de Genève
Geneva, Switzerland, 1211
Sponsors and Collaborators
Duke University
Medifacts International Corporation
Principal Investigator: Stefan Sack, Md, PhD Klinikum Schwabing, Staedtisches Klinikum Muenchen GmbH
Principal Investigator: Rainer Hoffmann, MD R-WTH Universitätsklinikum Aachen
  More Information

Additional Information:
Responsible Party: Katharine M Stohlman, Viacor, Inc. Identifier: NCT00787293     History of Changes
Other Study ID Numbers: 08-010P
Study First Received: November 5, 2008
Last Updated: February 10, 2011

Keywords provided by Viacor:
Heart Failure
Mitral Regurgitation
Coronary sinus

Additional relevant MeSH terms:
Heart Failure
Mitral Valve Insufficiency
Heart Diseases
Cardiovascular Diseases
Heart Valve Diseases processed this record on August 17, 2017